Search peptides, terms, sources/
Growth hormone axis

Ipamorelin

Also known as: IPA

Synthetic growth hormone secretagogue studied for growth hormone release. Not licensed in the UK; human evidence is one small pharmacokinetic study.

UK status checked . Evidence last reviewed . By the PeptGuru editorial team (Astute Management).

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Limited evidence (level 2 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

1 finding at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Ipamorelin is recorded as not licensed in the UK (checked 14 November 2026).

Best study type
Human trials1 human trial

What is Ipamorelin?

Ipamorelin is a synthetic peptide that activates the growth hormone secretagogue receptor, studied for its effect on growth hormone release. It is not licensed in the UK, and the only human evidence identified is one pharmacokinetic study in healthy men and a registered trial with no published outcome identified.

It is a five-amino-acid peptide (pentapeptide) that acts on the GHS-R1a receptor and has been studied for its effect on growth hormone release.

Class
Growth hormone secretagogue (GHS) pentapeptide
Origin
Fully synthetic
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does Ipamorelin work?

Ipamorelin activates the receptor for ghrelin, a natural hormone, on the pituitary gland, which then releases growth hormone. Animal studies suggest it does this without raising other pituitary hormones such as cortisol. A single human study found a short burst of release at each level tested.

The mechanism in more detail

Ipamorelin binds and activates the growth hormone secretagogue receptor subtype 1a (GHS-R1a), the same receptor activated by the body’s own hormone ghrelin, stimulating the pituitary gland to release growth hormone. The pharmacology paper that first described the compound reported it as a selective secretagogue: in animal studies it released growth hormone with potency comparable to an earlier compound, GHRP-6, but without the accompanying rise in ACTH, cortisol, FSH, LH, prolactin or TSH that earlier growth hormone-releasing peptides produced.

Human evidence for this mechanism comes from a single pharmacokinetic and pharmacodynamic study in healthy male volunteers, using intravenous dosing. That study reported dose-proportional pharmacokinetics and a single, time-limited episode of growth hormone release at every dose tested, consistent with preservation of the body’s natural pulsatile pattern of growth hormone secretion rather than sustained elevation. This remains the only human clinical data identified for ipamorelin to date, and it has not been independently replicated by a separate research group.

Mechanisms and targets

Ghrelin receptor (GHS-R1a) agonismGrowth hormone (GH) pulsatile releaseSelective secretagogue (no ACTH/cortisol/prolactin co-elevation reported)GHS-R1a (growth hormone secretagogue receptor 1a)

Classification and structure

Names
Ipamorelin; IPA
Class
Growth hormone secretagogue (GHS) pentapeptide
Origin
Fully synthetic
Structure
Pentapeptide, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2.
Routes used in the research
Intravenous infusion in the human pharmacokinetic study. Injectable administration in the registered postoperative-ileus trial. This reflects study methodology, not a usage instruction.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Ipamorelin has 2 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

2 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
11000

Healthy male pharmacokinetic study Limited

In a human dose-escalation pharmacokinetic and pharmacodynamic study (8 healthy male subjects per dose level, 5 dose levels by intravenous infusion), ipamorelin produced dose-proportional pharmacokinetics (terminal half-life approximately 2 hours) and a single, time-limited episode of growth hormone release at every dose level tested, with an exponential decline back to negligible growth hormone concentration, consistent with preservation of the natural pulsatile growth hormone-release pattern rather than sustained elevation.

Study type
Human trial
Population
Human, healthy male volunteers, dose-escalation design, 8 subjects per dose level (5 dose levels)
Source
1 Gobburu et al., 1999

Limitation: Single PK/PD study, healthy male subjects only (no female, elderly or clinical-population data identified), acute single-dose/short-infusion design rather than a repeated-dosing efficacy trial, not independently replicated.

Limitations in full

Single PK/PD study, healthy male subjects only (no female, elderly or clinical-population data identified), acute single-dose/short-infusion design rather than a repeated-dosing efficacy trial, not independently replicated. Evidence strength is rated Limited because this is a single study.

Registered postoperative ileus trial Preliminary

Ipamorelin was investigated in a registered Phase II, double-blind, placebo-controlled, multiple-dose clinical trial (sponsor: Helsinn Therapeutics) for management of postoperative ileus (delayed return of bowel function after surgery), running April 2008 to December 2009. This documents that a controlled human efficacy trial for a specific clinical indication was conducted; it is not, by itself, evidence of a positive or negative result, since the trial's outcome could not be independently verified against a peer-reviewed publication.

Study type
Clinical trial registry entry
Population
Human, post-surgical patients, Phase II, double-blind, placebo-controlled, multiple-dose
Source
2 ClinicalTrials.gov

Limitation: This finding records that a Phase II trial was conducted.

Limitations in full

This finding records that a Phase II trial was conducted. It does not establish an efficacy or safety result. The outcome has not been confirmed from a publication or registry results posting.

What safety findings have been reported?

No safety findings are recorded for Ipamorelin yet. That is not evidence of safety.

What is Ipamorelin's UK regulatory status?

Marketing authorisation
No UK marketing authorisation found. Not a licensed medicine. A check of the MHRA Products database active substance index on 14 November 2026 found no entry for ipamorelin.
Prescription status
Not applicable, no licensed UK product was found to classify. If licensed, growth hormone secretagogues of this type would be expected by default to be classified as prescription-only medicines, an inference from general secondary-source characterisation, not a confirmed MHRA statement.
Medicine class
Not classified as a licensed medicine; treated by the MHRA as unlicensed where sold or supplied with medicinal claims.
MHRA position
No ipamorelin-specific MHRA enforcement notice, Yellow Card FOI data, or public assessment report was located. Unlicensed supply for human use is unlawful under the Human Medicines Regulations 2012 on the same general-framework basis as other unlicensed peptides in this batch.
Authorised use
None.
Other restrictions
In sport, the WADA 2026 Prohibited List (in force from 1 January 2026) names ipamorelin under S2.2.4, growth hormone secretagogues.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Ipamorelin is recorded as not licensed in the UK (checked 14 November 2026).

References

3 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Gobburu JV, et al. (1999). Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers. Pharmaceutical ResearchHuman clinical trial · DOI 10.1023/A:1018955126402 · PMID 10496658 · Original ↗
  2. ClinicalTrials.gov Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus. ClinicalTrials.govClinical trial registry entry · Original ↗
  3. Medicines and Healthcare products Regulatory Agency (MHRA) (2026). MHRA Products database: active substance index (A to Z), checked 14 November 2026. MHRA Products database · Original ↗

Questions about Ipamorelin

What is Ipamorelin?

Ipamorelin is a synthetic peptide that activates the growth hormone secretagogue receptor, studied for its effect on growth hormone release. It is not licensed in the UK, and the only human evidence identified is one pharmacokinetic study in healthy men and a registered trial with no published outcome identified. Read what it is.

Is Ipamorelin licensed in the UK?

PeptGuru records Ipamorelin's UK status as: Not licensed in the UK. No UK marketing authorisation found. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Ipamorelin show?

PeptGuru records 2 research findings for Ipamorelin: 1 from a human trial and 1 from a regulatory or other record. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Ipamorelin?

No safety findings are recorded yet. That is not evidence of safety. Read the safety findings.

Where are the sources for Ipamorelin?

All 3 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • Regulatory update · UK status now cites a dated MHRA database check. WADA 2026 listing added (S2.2.4).

How findings are graded: the grading method. All changes.

  • GHRP-2Pralmorelin

    Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK; Japan licenses it only as a diagnostic test. No trial shows a health benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • GHRP-6Growth hormone-releasing…

    Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK. Human studies are short hormone-response and diagnostic work; no trial shows a health benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • HexarelinExamorelin

    Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK. In a long-term human study the response faded and IGF-I and body composition did not change.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • AOD-9604hGH Fragment 176-191

    Growth hormone fragment studied for weight management. Not licensed in the UK; its largest human trial showed no significant weight-loss benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    ModerateNot licensed in the UK

Compare Ipamorelin with GHRP-2

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.